Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00289 ...
Drug Name Atomoxetine
Molecular Weight 255.3547
Molecular Formula C17H21NO
CAS Number 83015-26-3
SMILES CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
External Links
DRUGBANK DB00289
T3DB T3D2737
PubChem Compound 54841
PDR 294
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.676 - 0.676 - 'MSDS'
Boiling Point 64.5 ℃ 64-65 ℃ 'MSDS'
Melting Point 163.0 ℃ 161-165 ℃ 'MSDS'
Water Solubility 27800.0 mg/L 27.8 mg/ml Yu G., Li G. and Markowitz J. 2016. J Child Adolesc Psychopharmacol.
pKa 10.13 - 10.13 - Atomoxetine. Eli Lilly product monograph.

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 2000.0 ng.h/ml 2.0 mcg.h/ml PO, oral; DRUGBANK
Bioavailability 63.0 % 63.0 % PO, oral; DRUGBANK
Bioavailability 94.0 % 94.0 % PO, oral; high-fat meal; high-fat meal ↑ ; DRUGBANK
Bioavailability 63.0 % 63.0 % PO, oral; extensive metabolizers, EM; The Pharmacological Basis of Therapeutics
Bioavailability 94.0 % 94.0 % PO, oral; poor metabolizers, PM; The Pharmacological Basis of Therapeutics
C Max 350.0 ng/ml 350.0 ng/ml PO, oral; DRUGBANK
C Max 160.0 ng/ml 160.0 ng/ml PO, oral; extensive metabolizers, EM; The Pharmacological Basis of Therapeutics
C Max 915.0 ng/ml 915.0 ng/ml PO, oral; poor metabolizers, PM; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1-2 h PO, oral; DRUGBANK
T Max 2.0 h 2.0 h PO, oral; poor metabolizers, PM; extensive metabolizers, EM; The Pharmacological Basis of Therapeutics
Clearance 0.47 L/h/kg 0.27-0.67 L/h/kg DRUGBANK
Clearance 0.37 L/h/kg 6.2 ml/min/kg apparent clearance; at steady state; hydrolysis; extensive metabolizers, EM; hepatopathy，LD ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.0360 L/h/kg 0.6 ml/min/kg apparent clearance; at steady state; hydrolysis; poor metabolizers, PM; The Pharmacological Basis of Therapeutics
Clearance 0.56 L/h/kg 9.3 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 2.1 L/kg 1.6-2.6 L/kg PO, oral; DRUGBANK
Volume of Distribution 0.85 L/kg ~0.85 L/kg Steady state volume of distribution; intravenous injection, IV; DRUGBANK
Volume of Distribution 2.3 L/kg 2.3 L/kg Apparent volume of distribution; at steady state; hydrolysis; extensive metabolizers, EM; The Pharmacological Basis of Therapeutics
Volume of Distribution 1.1 L/kg 1.1 L/kg Apparent volume of distribution; at steady state; hydrolysis; poor metabolizers, PM; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.85 L/kg 0.85 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 4.3 h 3-5.6 h CYP2D6 genetic polymorphisms; DRUGBANK
Half-life 5.3 h 5.3 h extensive metabolizers, EM; at steady state; The Pharmacological Basis of Therapeutics
Half-life 20.0 h 20.0 h poor metabolizers, PM; at steady state; The Pharmacological Basis of Therapeutics
Half-life 5.2 h 5.2 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 80.0 % >80 % Urinary excretion; DRUGBANK
Eliminate Route 17.0 % <17 % Faeces excretion; DRUGBANK
Eliminate Route 3.0 % <3 % Unchanged drug; DRUGBANK
Eliminate Route 1.5 % 1-2 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 98.7 % 98.7 % plasma proteins; DRUGBANK
Protein Binding 96.2 % ~96.2 % DRUGBANK
Protein Binding 98.7 % 98.7±0.3 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 100.0 mg/day 100 mg/day PO, oral Strattera atomoxetine PDR
Max dose for children 1.4 mg/kg/day 1.4 mg/kg/day PO, oral Strattera atomoxetine PDR
Max dose for adolescents 1.4 mg/kg/day 1.4 mg/day/kg PO, oral Strattera atomoxetine PDR
Max dose for adolescents 100.0 mg/day 100 mg/day PO, oral Strattera atomoxetine PDR
Max dose for adults 100.0 mg/day 100 mg/day PO, oral Strattera atomoxetine PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1